The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Siddhesh Anant Nayak
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Siddhesh Anant Nayak, a member of the promoter group of Clinitech Laboratory Ltd, purchased 2,400 equity shares of the company through the open market on August 18, 2025. His holding in the company rose from 55,500 shares (2.43%) to 57,900 shares (2.54%) of the total equity share capital. The total equity capital of the company stands at 22,82,400 shares. This is a routine SAST Regulation 29(2) disclosure by a promoter group member for a small incremental acquisition.
This is a minor purchase of just 0.11% of the company and is unlikely to materially affect the stock price. It signals continued promoter group confidence but the size is too small to carry significant weight for retail investors.